A recent Phase II trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The label expansion for the anti-CD38 antibody was supported by data from the ongoing Phase III PERSEUS trial that was submitted to to the European Medicines Agency in March 2024. Darzalex ...

The French pharma group has filed anti-CD38 antibody Sarclisa (isatuximab) for use in combination with Takeda’s Velcade (bortezomib), lenalidomide, and dexamethasone – known as the VRd regimen ...

Treatment for relapsed or refractory multiple myeloma includes anti-CD38 antibodies, immunomodulating agents, CAR-T cell therapies, and bispecific antibodies, with evolving options enhancing patient ...

Daratumumab binds to CD38 and inhibits the growth of CD38 expressing ... lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody ...

In addition, the J&J anti-CD38 antibody also reduced the risk of needing first-line multiple myeloma treatment by 42% compared with active monitoring. As of the data cutoff, 64 patients (33% ...

and anti-CD38 antibodies. Equecabtagene autoleucel (eque-cel), an investigative fully human-derived B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...

Genmab also used the call to provide an update on GEN3014, the anti-CD38 monoclonal antibody that could be a successor to multiple myeloma powerhouse Darzalex. Johnson & Johnson, which developed ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...